THRX

Theseus Pharmaceuticals, Inc. (THRX) | Rumor.io

Theseus Pharmaceuticals

THRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about THRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Dec 22

Theseus Pharmaceuticals, Inc. ($THRX) has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire THRX for $3.90-$4.05 per share in cash, plus a contingent value right (CVR).
The CVR represents the right to receive 80% of the net proceeds from any license or disposition of THRX's programs within 180 days of closing, and 50% of the potential aggregate value of certain specified cost savings.
The acquisition is expected to close by January 9, subject to certain conditions, including the tender of at least a majority of THRX's outstanding shares and the availability of at least $187.6M of cash at closing.

Generated by AI

Sentiment

Of the messages about THRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Bullish· Nov 14

$THRX has a low float of 36M, which could contribute to its volatility and potential for a significant price move.
The stock's recent price action has been encouraging, with a big bidder stepping in at $3.17 and the price reversing off of $2 to trade at $3.30.
$THRX has a low short float of 8.2%, which could be a bullish sign and potentially contribute to a short squeeze move.

Bearish· Jul 14

$THRX has a significant cash reserve of $234 million, but its cancer treatment was withdrawn from Phase 1/2 trials, leading to a massive over-correction.
The company's financials show a burn rate of $17 million every 3 months, which could be a concern for investors, especially if the stock doesn't rebound soon.
The stock has plummeted by 65% in the premarket, with some analysts downgrading their price target or recommending a hold rating, suggesting a bleak outlook for the company.

Generated by AI

Topics

Of the messages about THRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Dec 22

Theseus Pharmaceuticals, Inc. (THRX) has agreed to be acquired by Concentra Biosciences for between $3.90 and $4.05 in cash per share, plus a contingent value right.
The acquisition price includes a base price of $3.90 per share and an additional $0.15 per share at closing, with the contingent value right representing 80% of net proceeds from any license or disposition of THRX programs within 180 days of closing.
The acquisition is expected to close in February 2024, with THRX shares rising 7% to $3.96 per share following the announcement.

Generated by AI

Community

Of the messages about THRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	0%
Newcomers	—	—	100%	100%

Also Discussed

Investors talking about THRX also mention

#	Name	Attention
1	Marti Technologies Inc.MRT	0%new
2	KNTE - Kinnate Biopharma Inc.	——
3	ChipMOS Technologies Inc. ADRIMOS	0.01%new
4	RDUS - Radius Recycling, Inc.	——
5	Celldex Therapeutics IncCLDX	0%+0
6	PRDS - Pardes Biosciences, Inc.	——
7	MRSN - Mersana Therapeutics, Inc.	——
8	RATE - Global X Interest Rate Hedge ETF	——
9	GSK plc ADRGSK	0%0
10	Ionis Pharmaceuticals, Inc.IONS	0%new